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Sir,
We read with interest the article of Morimoto et al (2004) that
investigated the relation of epigenetic inactivation of CIITA with
levels of HLA-DR, one of the MHC class II genes, in haematopoietic
tumour cells.
Recent DNA microarray studies have showed that decreased
levels of MHC class II molecules are associated with high
metastatic potential and/or poor prognosis, not only in haemato-
poietic tumour (Rimsza et al, 2004) but also in several
adenocarcinomas (Ramaswamy et al, 2003) and hepatocellular
carcinoma (HCC) (Iizuka et al, 2003), suggesting the common role
of MHC class II molecules in tumour progression. In this regard,
elegant work by Morimoto et al (2004) could provide a therapeutic
strategy against various malignancies. The authors stated that, by
suppressing the expression of MHC class II molecules, epigenetic
inactivation of CIITA provided a survival advantage to a subset of
haematopoietic tumours (Morimoto et al, 2004); however, they did
not investigate the relation between levels of CIITA and HLA-DR
and tumour progression.
Our recent DNA microarray study showed that decreased levels
of HLA-DRA gene were related to recurrence of HCC (Iizuka et al,
2003). We also confirmed that levels of HLA-DR protein by
tumour cells were related to recurrence of HCC (unpublished
data). Using the DNA microarray data set of HCC (available
at http://surgery2.med.yamaguchi-u.ac.jp/research/DNAchip/hcc-
recurrence/index.html), we investigated the relation between
levels of CIITA (three probes, U18288, U18259, and X74301) and
those of HLA-DRA (probe X00274) and HLA-DRB1 (probe
M33600). Given that CIITA levels in HCC were markedly low, it
is reasonable to assume that this phenomenon may be due in part
to its epigenetic inactivation. However, in our data, there were no
correlations between levels of CIITA and those of the two HLA-DR
genes. Thus, in the context of human cancer tissues, the
transcriptional regulation of HLA-DR is likely to be much complex.
From this standpoint, we recommend that the authors will clarify
the relation of CIITA methylation status to constitutive expression
of HLA-DR in a larger cohort of haematopoietic tumour. On the
basis of their finding (Morimoto et al, 2004) and our present
finding, in our opinion, methylation status of CIITA could be a
therapeutic target combined with interferon-gamma for preventing
the progression of haematopoietic tumour and HLA-DR may be
superior to CIITA as a marker for progression of haematopoietic
tumour.
Additionally, tumour HLA-DR might have a function other than
the antigen-presenting function. Recently, Altomonte et al (2003)
showed a possible involvement of HLA-DR in a signalling pathway
linked to cell adhesion in melanoma cells. Thus, we expect that
further work by Morimoto et al would provide a clue to
incorporate MHC class II antigens into the mainstream of
molecular basis underlying tumour progression.
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